Indications for Triple Therapy in COPD

Patient Selection Criteria

The American Thoracic Society recommends triple therapy LAMA/LABA/CSI for patients with stable COPD who have a high risk of exacerbations (≥2 moderate or ≥1 severe exacerbation in the past year), moderate to high symptom burden (CAT ≥10 or mMRC ≥2), and impaired lung function (FEV1 <80% predicted), as it reduces mortality compared to dual therapy LAMA/LABA 1, 2
Patients should have a high risk of exacerbations, defined as ≥2 moderate exacerbations (requiring antibiotics and/or oral corticosteroids) or ≥1 severe exacerbation (requiring hospitalization or emergency department visit) in the past year 1, 2
Patients should have a moderate to high symptom burden, defined as a CAT score ≥10 or an mMRC score ≥2 1, 2
Patients should have impaired lung function, defined as an FEV1 <80% predicted 1, 2

Triple therapy LAMA/LABA/CSI demonstrates a significant reduction in mortality compared to dual therapy LAMA/LABA, with moderate certainty of evidence 1, 2
Triple therapy reduces the annual rate of moderate or severe exacerbations to 0.91 compared to 1.21 for LAMA/LABA and 1.07 for CSI/LABA 3
Triple therapy reduces the rate of severe exacerbations to 0.13 per year compared to 0.19 per year for LAMA/LABA (hazard ratio 0.66; 95% CI 0.56-0.78) 3
Triple therapy provides additional benefits on dyspnea, health status, and lung function 1, 2

Patients with a low risk of exacerbations and mild symptoms (CAT <10, mMRC 1) should start with a single long-acting bronchodilator (LAMA or LABA) 1
Patients with a low risk of exacerbations and moderate to severe symptoms (CAT ≥10, mMRC ≥2) should start with dual therapy LAMA/LABA 1, 4
Patients with a high risk of exacerbations and moderate to severe symptoms (CAT ≥10, mMRC ≥2) should start with triple therapy LAMA/LABA/CSI 1, 2, 3

Patients with blood eosinophils ≥300 cells/μL benefit particularly from triple therapy with CSI 5
CSI should not be withdrawn from triple therapy in patients with a high risk of exacerbations, particularly if eosinophils are ≥300 cells/μL, as this increases the risk of moderate to severe exacerbations 3, 4

The incidence of pneumonia is slightly higher with regimens containing CSI, but the benefit-risk ratio favors triple therapy in appropriate patients (number needed to treat of 4 to prevent one moderate to severe exacerbation versus number needed to harm of 33 to cause one pneumonia) 5
Patients who are current smokers, aged ≥55 years, have a history of exacerbations or pneumonia, have a BMI <25 kg/m², and have severe airflow limitation should be monitored closely 5

The Canadian Thoracic Society recommends against adding theophylline to patients already on LAMA/LABA therapy due to the low certainty of benefits and the high risk of adverse effects and drug interactions 5
Moderate doses of CSI (e.g., budesonide 320 μg in the ETHOS study) have demonstrated a benefit on mortality without requiring higher doses 5

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends triple therapy combining a LAMA/LABA/ICS in a single inhaler as the initial maintenance therapy for COPD patients with high exacerbation risk, moderate-to-high symptom burden, and impaired lung function 6, 7

The American Thoracic Society acknowledges that fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 mcg once daily demonstrated a 25% reduction in annual moderate/severe exacerbations compared to LAMA/LABA dual therapy and a 15% reduction compared to ICS/LABA therapy in the IMPACT trial 6, 7
The European Respiratory Society notes that budesonide/glycopyrronium/formoterol fumarate triple therapy reduced the annual rate of moderate or severe exacerbations by 24% compared to LAMA/LABA dual therapy, with a demonstrated mortality benefit at this moderate ICS dose 6, 7

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) defines high risk as ≥2 moderate exacerbations or ≥1 severe exacerbation in the past 12 months, and low risk as ≤1 moderate exacerbation without hospitalization in the past 12 months 6, 8
The American College of Chest Physicians recommends assessing symptom burden, with moderate-to-high symptoms defined as CAT score ≥10 or mMRC score ≥2 6

The Canadian Thoracic Society guidelines strongly prefer single-inhaler triple therapy (SITT) over multiple-inhaler combinations due to improved adherence, reduced inhalation technique errors, and simplified treatment regimen 8

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) explicitly recommends against using ICS monotherapy in stable COPD patients at low risk of exacerbations 8